Published online Feb 6, 2019. doi: 10.12998/wjcc.v7.i3.340
Peer-review started: October 13, 2018
First decision: October 18, 2018
Revised: November 11, 2018
Accepted: November 23, 2018
Article in press: November 24, 2018
Published online: February 6, 2019
Processing time: 109 Days and 9.6 Hours
Adrenal primitive neuroectodermal tumor (PNET) is an extremely rare malignant tumor with poor prognosis and of neural crest origin. Herein, we report a case of adrenal PNET and summarized its clinical and pathological characteristics on the basis of 16 patients reported recently.
A female patient aged 25 years presented with right lumbago for 12 mo, and pre-operative computed tomography showed a huge right adrenal mass. She received tumorectomy, and post-operative pathological examination showed adrenal PNET. After surgery, she underwent adjuvant chemotherapy and was followed up 31 mo after surgery. She received brachytherapy for right paracolic and hepatic metastases. She was alive and followed up for 60 mo. In available studies, only 57.14% (4/7) and 44.44% (4/9) were positive for the expression of neuron-specific enolase and synaptophysin, respectively, although CD99 expression was found in all the patients (100%; 10/10).
It is concluded that adrenal PNET is very rare and highly malignant, and histology is a golden standard in its diagnosis. Surgery and adjuvant therapy is the main treatment.
Core tip: Primitive neuroectodermal tumor (PNET), a member of small round blue cell tumors, is very rare and highly malignant. PNET originating from the adrenal is extremely rare and only a few cases have been reported. The outcome of adrenal PNET is poor, standard treatments have never been established, and the efficacy of adjuvant chemotherapy and radiotherapy after operation is still unclear. Herein, we reported a case of adrenal PNET in a female patient who was alive after 60 mo of follow-up. We hypothesize that early removal and chemotherapy provided the excellent outcome of the patient.